Improve Research Reproducibility A Bio-protocol resource
Concise Method
tooltip

2.2.2. AvCoV-O

PL Priscila Diniz Lopes
CO Cintia Hiromi Okino
FF Filipe Santos Fernando
CP Caren Pavani
VM Viviane Casagrande Mariguela
MM Maria de Fátima Silva Montassier
HM Hélio José Montassier
ask Ask a question
Favorite

The AvCoV-O vaccine was prepared (v/v) by incorporating 70% of the adjuvant Montanide ISA 71 (SEPPIC, Inc., Fairfield, CT, USA) and 30% of the virus in AF to obtain a water-in-oil emulsion [24].

Copyright and License information:  ©2021 by the authors.
Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

Do you have any questions about this protocol?

Post your question to gather feedback from the community. We will also invite the authors of this article to respond.

post Post a Question
0 Q&A